Stephanie J. Lee, MD, MPH; Karen M. Kuntz, ScD; Mary M. Horowitz, MD, MS; Philip B. McGlave, MD; John M. Goldman, DM; Kathleen A. Sobocinski, MS; Janet Hegland, BS; Craig Kollman, PhD; Susan K. Parsons, MD, MRP; Milton C. Weinstein, PhD; Jane C. Weeks, MD, MS; Joseph H. Antin, MD
Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, et al. Unrelated Donor Bone Marrow Transplantation for Chronic Myelogenous Leukemia: A Decision Analysis. Ann Intern Med. 1997;127:1080-1088. doi: 10.7326/0003-4819-127-12-199712150-00005
Download citation file:
Published: Ann Intern Med. 1997;127(12):1080-1088.
Chronic myelogenous leukemia (CML) is an indolent but ultimately fatal disease. Because the natural history of CML varies and quality of life with CML may be excellent until shortly before death, deciding whether and when to pursue unrelated donor bone marrow transplantation is often difficult.
To compare early transplantation, delayed transplantation, and no transplantation for patients with chronic-phase CML on the basis of discounted, quality-adjusted life expectancy.
A Markov model comparing different strategies was constructed. This model considers patient age, quality of life, risk aversion, and the competing risks for CML progression and transplant toxicity.
Therapeutic decision at the time of diagnosis of CML.
The base case is a 35-year-old patient with intermediate-prognosis CML. Younger and older patients with better and worse prognoses are also evaluated.
Early transplantation, delayed transplantation, and no transplantation.
Quality-adjusted, discounted life expectancy.
For patients with newly diagnosed CML, transplantation within the first year provides the greatest quality-adjusted expected survival, although this benefit decreases with increasing patient age. For a 35-year-old patient with intermediate-prognosis CML, transplantation within the first year results in 5.3 more discounted, quality-adjusted years of life expectancy than does no transplantation. This finding is robust even with varying baseline assumptions.
These results support the use of early unrelated donor bone marrow transplantation for most patients with CML.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only